A national risk analysis model (NRAM) for the assessment of COVID‐19 epidemic
Qing Deng(Central South University), Yi Liu(China People's Public Security University), Xingyu Xiao(University of Science and Technology Beijing), Hui Zhang(Harbin Engineering University), Kai Liu(University of Science and Technology Beijing), Xue Cao(Xinjiang Medical University), Huiling Jiang(University of Science and Technology Beijing), Lin Zhu(University of Science and Technology Beijing), Feng Yu(Shanghai Jiao Tong University), Lida Huang(Tsinghua University)
Cited by 4
Related Papers
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Synthesis of China's land use in the past 300years
|Global and Planetary Change|2012|59
Just in Time/Lean Purchasing Approach: An Investigation for Research and Applications
|Journal of Advanced Management Science|2019|34
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions
|Cancer Cell|2024|28
Tomato yellow leaf curl virus: Characteristics, influence, and regulation mechanism
|Plant Physiology and Biochemistry|2024|23